Position in CYTK
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$39,013,271
+$25,909,638 QoQ
Shares Held
457,956
+130.3% QoQ
Ownership
0.329%
of shares outstanding
% of Portfolio
0.92%
of 13F equity value
Holder Rank
#62
of 473 holders
Holding Since
Jun 2022
7 quarters on record
Voting authority
Sole 75%
Shared 0%
None 25%
Common Shares in CYTK Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026EMERALD ADVISERS, LLC holds $600,984,884 across 23 Biotechnology names. CYTK ranks #6 (6.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
1,600,886 | $90,946,333 | |
| 2 | CORT |
Corcept Therapeutics Inc
|
748,325 | $65,066,858 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
1,603,319 | $62,048,445 | |
| 4 | MIRM |
Mirum Pharmaceuticals, Inc.
|
468,295 | $54,823,295 | |
| 5 | SYRE |
Spyre Therapeutics, Inc.
|
567,430 | $50,376,435 | |
| 6 | CYTK |
Cytokinetics Inc
This page
|
457,956 | $39,013,271 | |
| 7 | MANE |
Veradermics, Inc
|
288,370 | $35,452,207 | |
| 8 | PVLA |
Palvella Therapeutics, Inc.
|
229,486 | $35,070,050 |
All Filings in CYTK
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $39,013,271 | 457,956 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $13,103,633 | 198,811 | Shares | Sole | 2026-05-04 | |
| 2024-03-31 | $6,419,341 | 91,561 | Shares | Sole | 2024-05-08 | |
| 2023-03-31 | $8,361,742 | 237,617 | Shares | Sole | 2023-05-04 | |
| 2022-12-31 | $21,641,244 | 472,310 | Shares | Sole | 2023-02-03 | |
| 2022-09-30 | $16,502,554 | 340,610 | Shares | Sole | 2022-10-25 | |
| 2022-06-30 | $5,669,939 | 144,310 | Shares | Sole | 2022-07-29 | |
| No filing history on record for this holder in this stock. | ||||||